Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment Reporting Information [Line Items]
Total revenues	$ 15,583	$ 14,042
Cost of product revenue	4,391	3,825
Research and development	8,016	7,178
Selling, general and administrative	8,415	7,746
Total costs and operating expenses	20,822	18,749
Loss from operations	(5,239)	(4,707)
Depreciation and amortization	(319)	(238)
Loss before income taxes	(5,133)	(4,696)
Stock-based compensation	2,063	1,980
Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	10,087	10,729
Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	5,496	3,313
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	15,583	14,042
Cost of product revenue	4,391	3,825
Research and development	7,759	6,998
Selling, general and administrative	2,618	2,242
Total costs and operating expenses	14,768	13,065
Loss from operations	815	977
Stock-based compensation	777	396
Operating Segments [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	10,087	10,729
Cost of product revenue	4,391	3,825
Research and development	4,442	5,066
Selling, general and administrative	2,101	2,096
Total costs and operating expenses	10,934	10,987
Loss from operations	(847)	(258)
Stock-based compensation	636	333
Operating Segments [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	5,496	3,313
Cost of product revenue	0	0
Research and development	3,317	1,932
Selling, general and administrative	517	146
Total costs and operating expenses	3,834	2,078
Loss from operations	1,662	1,235
Stock-based compensation	141	63
Corporate [Member]
Segment Reporting Information [Line Items]
Total costs and operating expenses	5,575	5,435
Depreciation and amortization	(373)	(238)
Product Sales [Member]
Segment Reporting Information [Line Items]
Total revenues	7,988	6,163
Product Sales [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	7,988	6,163
Product Sales [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	0	0
Product Sales [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	7,988	6,163
Product Sales [Member] | Operating Segments [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	7,988	6,163
Product Sales [Member] | Operating Segments [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	0	0
Research and Development Revenue [Member]
Segment Reporting Information [Line Items]
Total revenues	7,595	7,879
Research and Development Revenue [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	2,099	4,566
Research and Development Revenue [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	5,496	3,313
Research and Development Revenue [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	7,595	7,879
Research and Development Revenue [Member] | Operating Segments [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	2,099	4,566
Research and Development Revenue [Member] | Operating Segments [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	$ 5,496	$ 3,313